-
Explore the Latest Developments in Bronchiectasis During ATS 2026 Orlando
on
In August 2025, clinicians and researchers who treat patients with bronchiectasis reached a significant milestone with the FDA approval of brensocatib, the first treatment developed for non-cystic fibrosis bronchiectasis in adults and pediatric patients aged 12 and older. In an interview with ATS Conference News, Dan Belz, MD, MPH, explained the significance of this milestone and highlighted several key sessions exploring critical aspects of bronchiectasis at the ATS 2026 International Conference.
More #ATS2026 News
-
ATS Diversity Forum Speaker to Explore Resilience in a Time of Challenge
on
The annual ATS Diversity Forum celebrates diversity in pulmonary, critical care, and sleep medicine and offers accessible career insights and networking opportunities in a welcoming environment. This year’s featured speaker is Jennifer L. Taylor, MD, MSCS, ATSF, who will explore the theme, “Resilience in a Time of Challenge.” This year’s event is scheduled for 11:45…
-
Women’s Forum Panel Highlights Real-World Strategies for Career and Professional Growth
on
The Women’s Forum at the ATS 2026 International Conference is introducing a new twist: For the first time, the Forum will feature a talk-show format with five distinguished panelists. The discussion will focus on numerous crucial topics, offering practical perspectives to spur personal and professional growth. The event will be held from 11:45 a.m. –…